Neoleukin Therapeutics Inc

NASDAQ:NLTX  
0.42
+0.01 (+1.30%)
4:39:43 PM EDT: $0.42 0.00 (0.00%)
Earnings Announcements

Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results

Published: 11/14/2022 21:53 GMT
Neoleukin Therapeutics Inc (NLTX) - Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update.
Neoleukin Therapeutics Inc - Company Restructuring to Extend Cash Runway Into Second Half of 2025.
Neoleukin - Cash, Cash Equivalents, and Short-term Investments Totaled $106.9 Million As of Sept 30, 2022, Compared to $142.5 Million As of Dec 31, 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.24

More details on our Analysts Page.